France: Acticor Biotech announces Euronext Growth IPO plans

Acticor Biotech, a clinical stage biopharmaceutical company specialising in the development of drugs for treating the acute phase of thrombotic diseases, has received approval for its projected IPO on the Euronext Growth market in Paris. The firm is developing a first-in-class drug candidate, glenzocimab, with no hemorrhage risk, for which two Phase 2 clinical trials…

You must be a HMI Subscriber to view this content.

Subscribe Now »